Xilio Therapeutics (XLO) Cash from Operations (QoQ) (2021 - 2026)
Xilio Therapeutics (XLO) Cash from Operations (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - |
| 10 | Xilio Therapeutics | 149.09 Mn | -1.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,018.27% |
| Dec 31, 2025 | 88.58% |
| Sep 30, 2025 | -20.85% |
| Jun 30, 2025 | -149.96% |
| Mar 31, 2025 | 304.69% |
| Dec 31, 2024 | -3.55% |
| Sep 30, 2024 | -168.52% |
| Jun 30, 2024 | 289.99% |
| Mar 31, 2024 | 21.78% |
| Dec 31, 2023 | -0.43% |
| Sep 30, 2023 | 19.34% |
| Jun 30, 2023 | 34.36% |
| Mar 31, 2023 | -38.56% |
| Dec 31, 2022 | 8.47% |
| Sep 30, 2022 | -18.82% |
| Jun 30, 2022 | 19.58% |
| Mar 31, 2022 | -21.40% |
| Dec 31, 2021 | 17.17% |
| Sep 30, 2021 | -2.90% |
| Jun 30, 2021 | 11.43% |